<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005973</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02343</org_study_id>
    <secondary_id>ID99-304</secondary_id>
    <secondary_id>U01CA062461</secondary_id>
    <secondary_id>CDR0000067960</secondary_id>
    <nct_id>NCT00005973</nct_id>
  </id_info>
  <brief_title>BMS-214662 in Treating Patients With Solid Tumors</brief_title>
  <official_title>Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of BMS-214662 in treating patients who have solid&#xD;
      tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of BMS-214662 in patients with solid tumors.&#xD;
&#xD;
      II. Evaluate intermediate biological endpoints as surrogates for the effectiveness of this&#xD;
      drug in these patients.&#xD;
&#xD;
      III. Determine the nature of dose limiting toxicity of this drug in this patient population.&#xD;
&#xD;
      IV. Determine the recommended phase II regimen of this drug in these patients. V. Establish a&#xD;
      pharmacologic and pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every&#xD;
      6 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience&#xD;
      dose limiting toxicities.&#xD;
&#xD;
      Patients are followed every 3 months for at least 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD, defined as the dose level among the 9 levels studied having toxicity rate closest to a target of 33%, graded according to CTC version 2.0</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Toxicity is defined as grade 3, 4 non-hematologic and grade 4 hematologic (neutropenia and thrombocytopenia) toxicity. The continual reassessment method (CRM) will be used.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-214662</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>farnesyltransferase inhibitor BMS-214662</other_name>
    <other_name>FTI BMS 214662</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of malignant solid tumor for which a standard curative therapy does not&#xD;
             exist&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  No uncontrolled heart disease&#xD;
&#xD;
          -  No history of clinically significant cardiac arrhythmia that could be exacerbated by&#xD;
             QT interval prolongation&#xD;
&#xD;
          -  Corrected QT interval no greater than 450 milliseconds&#xD;
&#xD;
          -  Must not require total parenteral nutrition&#xD;
&#xD;
          -  No manifestations of malabsorption syndrome due to prior surgery, gastrointestinal&#xD;
             disease, or unknown reasons&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No signs or symptoms of acute infection requiring systemic therapy&#xD;
&#xD;
          -  No grade 3 or 4 neurotoxicity from prior anticancer treatment or neuropathy from any&#xD;
             cause&#xD;
&#xD;
          -  No confusion, disorientation, or psychiatric illness that may preclude study&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or&#xD;
             mitomycin) and recovered&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
&#xD;
          -  No concurrent hormonal anticancer therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Prior drugs known to prolong the QT interval allowed if they can be safely&#xD;
             discontinued for a time period equal to 4 elimination half-lives prior to&#xD;
             administering study drug&#xD;
&#xD;
          -  No drugs known to prolong the QT interval during and for 24 hours after study drug&#xD;
&#xD;
          -  No concurrent therapy with known CYP3A4 substrates&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassiliki Papadimitrakopoulou</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

